NH

Nick Hong

Angel Investor at Iterative Health

Nick Hong is an accomplished product management professional currently serving as the Director of Product Management at Coupang since 2022, where responsibilities include leading the Eat’s Ad Product organization, focusing on customer app ad placements, ad algorithms, and the merchant self-serve platform. Previously, Nick earned a promotion to Group Product Manager within a year, successfully spearheading the ETA ML product and Eats Rider app, and played a crucial role as a Senior Product Manager in the delivery domain. Prior experience includes leading monetization efforts at Soomgo and holding various finance-related roles at Thermo Fisher Scientific, where participation in a selective finance leadership development program took place. Additionally, Nick served as an angel investor at Iterative Health, contributing to an AI-driven startup in the medical field. Educational credentials include an MBA from MIT Sloan School of Management and a Bachelor of Science in Business Administration from Boston University's Questrom School of Business, along with an exchange program in China.

Links

Previous companies


Org chart

No direct reports

Teams

This person is not in any teams


Offices

This person is not in any offices


Iterative Health

1 followers

Iterative Health is pioneering the use of artificial intelligence-based precision medicine in gastroenterology (GI), with the aim of helping to optimize clinical trials investigating treatment of inflammatory bowel disease (IBD). We use advanced machine learning and computer vision to interpret endoscopic images along with other types of data, helping clinicians to better assess patients with potential GI problems. This gives practitioners enhanced capabilities in the detection, annotation, disease scoring and treatment of GI related diseases. Iterative Health is initially applying these advances towards standardizing disease severity characterization for inflammatory bowel disease. Ultimately, the company aims to establish more meaningful endpoints to serve as better predictors of both therapeutic response and disease outcomes. The company is headquartered in Cambridge, Massachusetts.


Employees

51-200

Links